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Background: Active vitamin D metabolite, 1, 25-dihydroxyvitamin D, has pleomorphic effects
on both innate and acquired immunity. Sarcoid granuloma derived 1, 25-dihydroxyvitamin D
leads to hypercalcemia, but the association of 1, 25-dihydroxyvitamin D with the clinical
phenotype of the disease is currently unknown.
Objective: To determine the relationship between serum 1, 25-dihydroxyvitamin D levels and
the degree of sarcoidosis disease chronicity.
Design: Serum 1, 25-dihydroxyvitamin D levels were measured and associated with sarcoidosis
activity and phenotypes as assessed by Sarcoidosis Severity Score and Sarcoidosis Clinical
Activity Classification respectively.
Results: Fifty nine patients were recruited with 44% having a sub-acute onset, and the chronic
disease phenotype. There was no significant difference in serum 1, 25-dihydroxyvitamin
D levels by chest radiograph stage (pZ 0.092) nor did the levels correlate with the Sarcoidosis
Severity Score (rZ 0.16; pZ 0.216). Serum 1, 25-dihydroxyvitamin D levels were associated
with patients requiring repeated regimens of systemic immunosuppressive therapy or >1 year
of therapy (SCAC Class 6). Increasing quartiles of serum 1, 25-dihydroxyvitamin D level was
associated increased odds of the chronic phenotype (OR 1.82, 95% CI, 1.11, 2.99,
pZ 0.019). The majority (71%) of the patients with levels >51 pg/mL required chronic immu-
nosuppressive therapy as defined by SCAC class 6.3) 916 2436; fax: þ1 (313) 916 9102.
(R. Burke).
9 Elsevier Ltd. All rights reserved.
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Sarcoidosis is a systemic inflammatory disease that
primarily affects the lung and lymphatic system of the
body. The clinical expression, natural history, and prognosis
of sarcoidosis are highly variable but depend upon a Th1
lymphocytic immune reaction due to an unknown anti-
gen(s).1,2 The subsequent granulomatous reaction can
coalesce resulting in progressive organ dysfunction.
The role of vitamin D, more specifically of its active
metabolite 1, 25-dihydroxyvitamin D, has been investigated
rather extensively in sarcoidosis, but mainly as an expla-
nation for hypercalcemia seen in 2e5% patients.3 Seasonal
sun exposure, iatrogenic ultraviolet irradiation, and vitamin
D supplementation provide excess 25-hydroxyvitamin D
through the actions of 25-hydroxylase in the liver.4,5 CD4þ
derived interferon-gamma has been shown to stimulate
macrophage 1a-hydroxylase enzyme resulting in increased
production of 1, 25-dihydroxyvitamin D, the metabolically
active form of vitamin D.6e9 Without the usual product
inhibition loop to reduce activated alveolar macrophage
1a-hydroxylase activity, excessive 1, 25-dihydroxyvitamin D
production leads to increased intestinal calcium absorption
(hyperabsorptive hypercalcemia), and to a lesser extent
increased bone resorption, although the mechanism for the
latter is less clear.9 In addition, reduction in serum 1, 25-
dihydroxyvitamin D levels by corticosteroid therapy
promptly reduces serum calcium levels.5
Increasingly, 1, 25-dihydroxyvitamin D has been investi-
gated as a potential immunomodulating hormone. There is
a reduction of T-cell proliferation and interleukin-2 and
interferon-g synthesis upon exposure to 1, 25-dihydrox-
yvitamin D3.10e14 In addition, antigen-presenting cells
(APC) become more tolerogenic with exposure to 1,
25-dihydroxyvitamin D.15,16 Contrary to the tolerogenic
effect of 1, 25-dihydroxyvitamin D on the adaptive immune
system, Hansdottir et al. have shown increased local
production of 1, 25-dihydroxyvitamin D by respiratory
epithelial cells leading to expression of immunogenic
proteins common to innate immunity.17 The potential
influence of these established immunomodulating proper-
ties of 1, 25-dihydroxyvitamin D have not been investigatedivity Classification.a
d for immunosuppressive thera
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f several periods of immunosup
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e period of treatment, not long
ed of several periods of immun
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ed 2008; 177:330e336.in sarcoidosis. Two possibilities could exist in the relation-
ship between 1, 25-dihydroxyvitamin D and sarcoidosis.
First, 1, 25-dihydroxyvitamin D may be associated with
increased sarcoidosis activity as a reflection of the overall
granulomatous disease burden and subsequent 1, 25-dihy-
droxyvitamin D production. Alternatively, 1, 25-dihydrox-
yvitamin D produced by the granulomatous response may
inhibit CD4þ inflammation by its immune modulating
properties and thus may be associated with less severe
disease. To the best of our knowledge, the relationship
between serum 1, 25-dihydroxyvitamin D levels and
sarcoidosis disease severity has not been investigated.
Accordingly, the objectives our study was to (1) determine
the correlation between serum 1, 25-dihydroxyvitamin D
levels and sarcoidosis disease activity, and (2) to determine
the association of serum 1, 25-dihydroxyvitamin D levels
with specific sarcoidosis clinical phenotypes.
Methods
All patients with a clinical-pathologic history of sarcoidosis
according to the American Thoracic Society (ATS) consensus
guidelines1 were recruited from the pulmonary clinic at the
Henry Ford Hospital between March 2004 and September
2007 a minimum of one year after diagnosis. Subjects were
excluded if they were taking multivitamins or supplemental
vitamin D. The consent and the study protocol were
approved by the Institutional Review Board.
Enrolled patients were characterized using two rubrics.
First, the Sarcoidosis Clinical Activity Classification (SCAC),
which classifies patients into 6 separate phenotypes as
determined by the following: a) acute versus non-acute
disease onset, b) need for treatment, and c) need for >1
year of treatment18 (Table 1).
To be included into the study and characterized by the
SCAC scheme, each patient must have had at least 2 years
of observed clinical care recorded in the electronic medical
record. The second rubric used was the Sarcoidosis Severity
Score (SSS), which summates race, percent predicted
Forced Vital Capacity (FVC), need for non-corticosteroid
immunosuppression, and the presence of cardiac and/or
neurologic disease, to establish a continuous score ofpy
sting than one year
pressive therapy or long lasting treatment (>12 months)
erapy
er lasting than one year
osuppressive therapy or long lasting treatment (>12 months)
C, Germann M et al. Phenotyping sarcoidosis from a pulmonary
Table 2 Study Population.
African-American n Z 50 Caucasian n Z 9
Female-no. (%) 36 (72%) 6 (67%) p Z 0.708b
Age-mean ( S.D.) 45.8 (9.7) 54 (10.8) p Z 0.0232a
Percent Predicted FVC-mean (S.D.) 86.4% (16%) 76.0% (15%) p Z 0.076a
Scadding Radiographic Class-no. (%)
0 15 (30%) 0 (0%)
1 16 (32%) 3 (33.3%)
2 15 (30%) 2 (22.2%)
3 4 (8%) 4 (44.4%) p Z 0.016b
SCAC Class-no.(%)
1 0 (0%) 0 (0%)
2 0 (0%) 0 (0%)
3 2 (4%) 0 (0%)
4 18 (36%) 3 (33.3%)
5 8 (16%) 3 (33.3%)
6 22 (44%) 3 (33.3%) p Z 0.648b
Lofgren’s Syndrome 3 0
Neurologic Disease-no. 3 0
Cardiac Disease-no. 3 0
a t-test.
b fisher’s test. This tests for the general association of Scadding radiographic stage or SCAC class with race.
566 D. Kavathia et al.disease severity.19 NHANES III predicted reference equa-
tions were used to calculate the percent predicted FVC.
The Scadding staging system was used for chest radiograph
scoring using the chest radiograph taken closet to time of
study enrollment.20
Serum 25-hydroxyvitamin D, the best available index of
vitamin D nutrition was measured by a direct, competitive
chemiluminiscent immunoassay (DiaSorin, Inc. Stillwater,
MN, USA) with a notional clinical reference range of
17e80 ng/mL21 Serum 1, 25-dihydroxyvitamin D was
measured by radioimmunoassay (Cat.no. 65100E, DiaSorin,
Inc. Stillwater, MN, USA) with a clinical reference range of
7e60 pg/mL using a blood sample taken at time of study
enrollment. Serum angiotensin converting enzyme (ACE)
level was measured by enzyme immunoassay using Olympus
AU400 by spectrophotometric method. (Warde Medical
Laboratory, Ann Arbor, MI, USA) with a clinical reference
range of 8e52 U/L.
Statistical analysis was performed using R Statistical
Package (r-project.org, Version R 2.8.1).
Descriptive statistics were used to report demographic
and clinical characteristics with mean and standard devia-
tion (S.D.) for normally distributed continuous variables
median and inter-quartile (IQR) range for duration of disease
at enrollment. Chi-square or Fisher’s exact tests were used
to determine if differences existed between race and
radiographic stage, SCAC class, and gender distributions.
Student’s t-tests were used to test for the differences in
continuous variables (age, percent predicted FVC, and SSS)
by race. One-way analysis of variance (ANOVA) was used to
test for the differences in serum 25-hydroxyvitamin D, 1, 25-
dihydroxyvitamin D, and ACE levels by Scadding chest
radiograph class and SCAC class. Pearson correlation coef-
ficients were used to correlate serum 1, 25-dihydrox-
yvitamin D levels with the Sarcoidosis Severity Score.Logistic regression was used to investigate the association
between 1, 25-dihydroxyvitamin D levels with medication
treatment>1 year or repeated courses of treatment (SCAC 6).
The initial analysis was a crude estimate of the association
between serum 1, 25-dihydroxyvitamin D and SCAC class 6.
For clinically useful interpretation, the serum 1, 25-dihy-
droxyvitamin D levels were further stratified into quartiles
and the data was re-analyzed with an unadjusted model and
a model adjusting for Scadding radiographic class, race, and
current immunosuppressive medication use. This model was
also utilized to test for the effect of disease duration at the
time of vitamin D assessment. Scadding radiographic class
was controlled for as a class variable. The results were
expressed as adjusted odds ratios of the association
between 1, 25-dihydroxyvitamin D quartiles with the SCAC
class 6. The lowest quartile was used as the referent for
significance testing. Angiotensin converting enzyme (ACE)
levels were also tested for associations with SCAC class 6.
The association of disease duration with continuous vitamin
D levels, at the time of study enrollment, was also investi-
gated utilizing correlation coefficients. This study was fun-
ded internally without industry support.Results
Sixty-two patients were recruited with 59 meeting the
observation criteria of >2 year. Consistent with our clinical
population in general, 85% of the study subjects were
AfricaneAmericans. (Table 2) The median time since the
diagnosis of sarcoidosis to the study enrollment was 35
months (IQRZ 12e90 months). The small Caucasian sample
had more advanced Scadding radiographic class
(pZ 0.016), but no difference in the percent predicted FVC
was found when compared to AfricaneAmericans
Table 3 A Comparison of 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D, and ACE level by Radiographic Class, Phenotypic
Class, and Race.
Comparison
Groups
No of
Subjects (nZ)
25-hydroxyvitamin D
(ng/ml) (mean  S.D.)
1, 25-dihydroxyvitamin D
(pg/ml) (mean  S.D.)
ACE (units/L)
(mean  S.D.)
Scadding Radiographic Class
0 15 10.53 (3.56) 48.33 (14.71) 45.07 (24.43)
1 19 9.77 (6.84) 36.95 (11.20) 66.59 (52.70)
2 17 11.64 (6.04) 43.00 (9.59) 89.53 (169.36)
3 8 15.63 (9.87) 41.00 (17.77) 64.13 (108.26)
p-valuea 0.190 0.092 0.702
SCAC Class
3 2 13.50 (7.78) 38.00 (15.56) 19.50 (27.58)
4 21 9.90 (5.00) 39.10 (11.27) 66.42 (58.68)
5 11 11.15 (6.82) 38.55 (11.50) 44.09 (38.10)
6 25 12.36 (7.60) 46.76 (14.52) 82.28 (146.66)
p-valuea,b 0.618 0.156 0.698
Race
Caucasian 9 21.67 (8.06) 42.56 (16.09) 32.89 (23.66)
African-American 50 9.43 (4.11) 42.14 (12.77) 73.89 (112.27)
p-valuec <0.001 0.932 0.283
a Analysis of Variance (ANOVA). Tests for significant differences in mean values of vitamin D levels or ACE by Scadding radiographic
class or SCAC class.
b Additional t-test comparison of 1, 25-dihydroxyvitamin D3 levels for SCAC 6 (47.2  14.7 pg/ml) vs. SCAC 3,4,5 (38.8  11.0 pg/ml)
(p Z 0.02).
c t-test of mean vitamin D or ACE levels by race group.
Figure 1 1, 25-dihydroxyvitamin D levels determined by
quartiles based on the 25th percentile, median, and 75th
percentile. Test for trend, p-value Z 0.019. y Chi-square test
of significance with reference level  33 pg/ml.
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(n Z 3) was uncommon as was the acute onset disease as
defined by the SCAC classes 1 through 3.
Association of serum vitamin D metabolite levels with
race, Scadding radiographic class, and disease Severity. The
mean (S.D.) serum 25-hydroxycholecalciferol level was
11.3  6.6 ng/mL and the mean serum 1, 25-dihydrox-
yvitamin D level was 42.2  13.2 pg/mL. Serum 1, 25-
dihydroxyvitamin D levels were normally distributed
without significant outliers as determined by visual
inspection of the QQ plot and the upper extreme value
(median þ 3*IQR). AfricaneAmericans had a lower mean
serum 25-hydroxyvitamin D level than Caucasians (9.4 vs.
21.7 ng/mL; p < 0.001) but similar serum 1, 25-dihydrox-
yvitamin D levels (42.1 vs. 42.6 pg/ml, pZ 0.93). (Table 3).
There was no significant difference in serum levels of 1,
25-dihydroxyvitamin D when the study subjects were clas-
sified based on chest radiograph stage (p Z 0.092) or
overall SCAC class distribution (p Z 0.16). In addition,
serum 1, 25-dihydroxyvitamin D levels correlated with
neither the Sarcoidosis Severity Score (r Z 0.16;
p Z 0.216) nor serum ACE levels (r Z 0.04, p Z 0.77).
Association of serum 1, 25-dihydroxyvitamin D levels and
SCAC 6. SCAC class 6 individuals had significantly highermean
(S.D) serum 1, 25-dihydroxyvitamin D levels compared to
those not classified as SCAC 6 (47.2 pg/ml  14.7 vs.
38.8 pg/ml  11.0 V; pZ 0.02). Our initial model was aimed
to determine if serum 1, 25-dihydroxyvitamin D levels are
associated with SCAC class 6. In the unadjustedmodel, 1, 25-
dihydroxyvitamin D was significantly associated with SCAC
class 6 with every 1 unit increase in serum 1, 25-dihydrox-
yvitamin D level increased the odds of SCAC class 6 by 1.05
(95% CI 1.008, 1.104, pZ 0.02).Serum 1, 25-dihydroxyvitamin D Strata and >1 Year
Treatment Needs. Given this general association and for
ease of clinical interpretation, serum 1, 25-dihydrox-
yvitamin D levels were divided into quartiles with the
resulting groups of <Z33, 34 to 40, 41 to 51, and
>52 pg/mL. For each 1, 25-dihydroxyvitamin D strata
increase above the lowest quartile, the odds of requiring
>1 year of treatment increased by 1.82 (95% CI, 1.11, 2.99;
p Z 0.02) (Fig. 1).
To control for potential confounders such as Scadding
radiographic class, race, and current immunsuppressive
medication an adjusted model was utilized. In the base
model, serum 1, 25-dihydroxyvitamin D level was still
Figure 2 Correlation of time since diagnosis and 1,
25-dihydroxyvitamin D levels.
568 D. Kavathia et al.associated with SCAC 6 after controlling for these
confounders (OR 2.71, 95% CI 1.18, 6.19, p Z 0.02). The
duration of disease had no impact on the 1, 25-dihydrox-
yvitamin D adjusted association with SCAC 6 as the adjusted
model (disease duration þ base model covariates) odds
ratio was not different from the base model (OR 2.81, 95%
CI, 1.2, 6.59, p Z 0.02). The highest quartile (>51 pg/mL)
of 1, 25-dihydroxyvitamin D was strongly associated with
SCAC class 6 (OR 8.12, 95% CI 1.62, 40.74, p Z 0.01) when
compared to the reference 1, 25-dihydroxyvitamin D level
(the lowest quartile). In addition, there was no association
between the duration of disease at recruitment and serum
1, 25-dihydroxyvitamin D levels (rZ 0.17; pZ 0.21; Fig. 2).
Seventy one percent of the patients with >51 pg/mL
required >1 year of therapy. Serum ACE levels were also
tested for crude associations with SCAC class 6, however no
significant association was found (OR 1.00, 95% CI 0.99,
1.01, 1.009, p Z 0.325).
Discussion
This study demonstrates that serum 1, 25-dihydroxyvitamin
D level is positively associated with a more chronic, sub-
acute onset sarcoidosis phenotype, independent of the
established predictors such as race and Scadding radio-
graphic class. This association is robust and not influenced
by current medication use or duration of the disease at
vitamin D assessment. In addition, we provide for the first
time, descriptive disease related data utilizing the recently
described Sarcoidosis Clinical Activity Classification and the
Sarcoidosis Severity Score in a cohort of predominantly
AfricaneAmericans.
The primary aim of our study was to determine if serum
1, 25-dihydroxyvitamin D levels are associated with
sarcoidosis severity and long-term treatment needs. We
have demonstrated that serum 1, 25-dihydroxyvitamin Dlevels are independently associated with the need for
multiple treatment courses or >1 year of therapy. The
highest quartile of 1, 25-dihydroxyvitamin D appears to be
driving most of the association. (Fig. 1) Considering that
the vitamin D metabolite levels were drawn at various
time points of care and not necessarily at diagnosis, we
cannot conclude with certainty that serum 1, 25-dihy-
droxyvitamin D levels are predictors of future disease
chronicity. However, the strong association (OR 8.12, 95%
CI 1.62, 40.74, p Z 0.01) of a serum 1, 25-dihydrox-
yvitamin D levels >51 pg/ml with SCAC 6 suggests
a discriminate ability to predict disease chronicity.
Prediction of future disease chronicity would require
a prospective study with assessment of serum 1, 25-dihy-
droxyvitamin D levels at diagnosis.
An ideal marker of sarcoidosis chronicity should be
easily obtainable (such as serum or urine), not altered by
current medication use, and could be assessed at any point
in the clinical course. In this study, we have demonstrated
that the association of serum 1, 25-dihydroxyvitamin D
levels, particularly >51 pg/ml, with chronicity is not
influenced by the current corticosteroid or immunosup-
pressant therapy (medication adjusted OR 2.71, 95% CI
1.18, 6.19, p Z 0.019). In addition, the duration of the
disease at the time of assessment did not influence the 1,
25-dihydroxyvitamin D levels. This is supported by regres-
sion modeling in which the adjusted odds ratio was not
altered by the disease duration at enrollment (OR 2.71 vs.
2.81) and a lack of correlation between enrollment disease
duration and serum 1, 25-dihydroxyvitamin D levels
(r Z 0.17, p Z 0.21).
Vitamin D, more specifically 1, 25-dihydroxyvitamin D,
has significant immunomodulatory properties, with known
effects on antigen-presenting cells (APC) and regulatory
T-cells.22 Non-obese diabetic (NOD) mouse experiments
have shown reduced expression of APC co-stimulatory
receptors CD40, CD80, and CD86 and decreased produc-
tion of the inflammatory IL-12 cytokine with exposure to
1, 25-dihydroxyvitamin D.16,15 This, in addition to
increased CD4þCD25þ regulatory T-cell levels, suggest 1,
25-dihydroxyvitamin D has tolerogenic effects on adap-
tive immunity.16,15,23,24 Extra renal sources of 1a-
hydroxylase activity have now been described.25 Respi-
ratory epithelial cells have shown constitutive and
inducible expression of 1a-hydroxylase.17 Through both
active and inactive forms of vitamin D, the production of
the toll like receptor (TLR) co-receptor CD14 and cath-
elicidin are increased, suggesting an accentuated innate
immune response. At the level of global disease, our data
suggest that elevated 1, 25-dihydroxyvitamin D levels are
associated with a more chronic disease course, reflecting
ongoing cytokine release, rather than the tolerogenic
effects of vitamin D.
In our study population of predominantly Africane
Americans (85%), serum 25-hydroxyvitamin D levels were
significantly lower in AfricaneAmericans compared to
Caucasians (9.4 vs. 21.7 ng/mL, p < 0.001) consistent with
the known higher prevalence of vitamin D deficiency in the
United States.26e28 In addition to a lower daily intake of
vitamin D, dark skin, insufficient sunlight exposure in
northern latitudes, and genetic variations in the vitamin D
binding protein gene are reported explanations for these
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are not likely explanation for differences in serum 25-
hydroxyvitamin D levels between AfricaneAmericans and
Caucasians since we excluded subjects who took vitamin D
supplementation.
Angiotensin converting enzyme levels have been inves-
tigated as a simple serum measure of sarcoidosis activity.
Our study is the first to determine the association of ACE
level with a validated measure of sarcoidosis severity (SSS
rubric). We found no association of ACE levels with global
disease severity (SSS) or with a chronic phenotype (SCAC
class 6).
We used the SSS described by Wasfi et al., which quan-
tifies commonly available data by the use of model
weighting to generate a continuous severity score. In our
study, serum 1, 25-dihydroxyvitamin D levels did not
correlate with SSS (r Z 0.16, p Z 0.22).19 This may be
explained by a lack of correlation between serum 1, 25-
dihydroxyvitamin D levels or Sarcoidosis Severity Score, or
both with granuloma burden. In addition, the SSS score is
heavily weighted by the presence of central nervous system
or cardiac disease involvement, both of which may not
require a heavy granuloma burden to cause a chronic,
symptomatic disease course or elevate the SSS.
Although our study suggests that elevated 1, 25-dihy-
droxyvitamin D levels are associated with a more chronic
sarcoid phenotype, this may not be simply due to a higher
granulomatous burden. We found no association of serum
1, 25-dihydroxyvitamin D levels with serum ACE levels, the
radiographic presence of parenchymal lung disease, or the
Sarcoidosis Severity Score. In addition, serum 1, 25-dihy-
droxyvitamin D levels were not different by Scadding
radiography classification or by race, the two factors we
have previously associated with increased lung granuloma
density.31 The influence of interferon-g in sarcoidosis and
its effects on the conversion of 25-hydroxyvitamin D to 1,
25-dihydroxyvitamin D production, could provide a partial
explanation for our observations. Serum 1, 25-dihydrox-
yvitamin D levels are tightly regulated by product inhibi-
tion of 1a-hydroxylase enzyme activity and accelerated
metabolic clearance rate of 1, 25-dihydroxyvitamin D by
24-hydroxylase.32 Interferon-g has been shown to increase
the production of 1, 25-dihydroxyvitamin D, induce resis-
tance to 1, 25-dihydroxyvitamin D in the autocrine feed-
back loop, and reduce expression of 24-hydroxylase mRNA
expression in activated macrophages.32,9 The presence of
interferon-g in the ongoing inflammatory milieu of
patients with persistent sarcoidosis could explain the
higher serum 1, 25-dihydroxyvitamin D levels in this group
(SCAC 6).
Sarcoidosis severity at diagnosis and the disease course
are different between race. AfricaneAmericans have more
advanced disease at the time of diagnosis based on forced
vital capacity, chest radiographic stage, extra-thoracic
involvement, and lung granuloma density compared to
Caucasians.3,31,33,34 In addition, AfricaneAmericans are
more likely to have a chronic disease course with a lower
frequency of disease remission and are more likely to
develop new organ involvement.33,3 Understanding the
mean values and distribution of the SSS and SCAC among
a large cohort of AfricaneAmericans is crucial in the design
and sample size estimates for future investigations. Weprovide these estimates as the earlier studies either had
low enrollment of AfricaneAmericans or did not provide the
ethnicity of the cohort.18,19
Limitations
Considering the cross-sectional nature of our study, many
subjects were on immunosuppressive therapy at the time of
vitamin D metabolite measurements. Since corticosteroids,
are known to reduce serum levels of 1, 25-dihydroxyvitamin
D, our study design would have underestimated the asso-
ciation between 1, 25-dihydroxyvitamin D and SCAC 6.9 Our
analysis adjusted for medication use found a stronger
association when controlled for current immunosuppressive
therapy (OR 1.7 vs. 2.7).
Our study found that serum 1, 25-dihydroxyvitamin D
level is positively associated with persistent or recurrent
medication therapy for sarcoidosis. One possible explana-
tion for this association is that the highest level of 1,
25-dihydroxyvitamin D leads to hypercalcemia, which is the
driver of long-term medication use (SCAC 6) rather than
chronic systemic or pulmonary disease. However, no
enrolled patient with a serum 1, 25-dihydroxyvitamin
D > 51 pg/mL and SCAC class 6 (n Z 10) had a serum Ca
>10.3 mg/dl at any time during the time of their observa-
tion nor had a previous treatment indication of
hypercalcemia.
By the nature of our study design where a two year
observation period was required for patient phenotyping,18
patients with limited follow-up such as a Lofgren’s
sarcoidosis phenotype or asymptomatic Scadding stage 0 or
I presentation were excluded. However, since our main
study objective was to investigate whether serum 1,
25-dihydroxyvitamin D levels were associated with chronic
sarcoidosis that requires more aggressive treatment,
exclusion of self-limiting disease from our study population
was not a limiting factor in testing our hypothesis.
Conclusion
Patientswith elevated serum1, 25-dihydroxyvitamin D levels
are likely to have more protracted treatment needs for their
sarcoidosis, independent of conventional predictors such as
race and Scadding radiographic patterns. Serum 1, 25-dihy-
droxyvitamin D should be assessed as a predictor of future
disease chronicity in a prospective study.
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